Advertisement

Medical Oncology

, Volume 29, Issue 5, pp 3321–3324 | Cite as

Objective response and time to progression on sequential treatment with sunitinib and sorafenib in metastatic renal cell carcinoma

  • Tomas Buchler
  • Tomas Pavlik
  • Zbynek Bortlicek
  • Alexandr Poprach
  • Rostislav Vyzula
  • Jitka Abrahamova
  • Bohuslav Melichar
Short Communication

Abstract

Patients with metastatic renal cell carcinoma (mRCC) are often treated sequentially with targeted agents, although the optimal strategy is not known. A retrospective, registry-based study has been carried out to assess correlation between clinical response and progression-free survival in patients with mRCC treated sequentially with tyrosine-kinase inhibitors (TKIs) sunitinib and sorafenib. Data on 218 mRCC patients treated with sunitinib and sorafenib who completed therapy with both TKIs were obtained from a database of mRCC patients. Standard nonparametric methods were used to assess correlation between response, PFS and length of treatment on the two agents. A strong correlation between responses to first- versus second TKI was observed (p < 0.001). No significant association was noted between the duration of therapy with the two TKIs (p = 0.056), although there was a weak statistically significant correlation between progression-free survival times in the subgroup patients who discontinued treatment because of disease progression. In conclusion, the duration of response on first TKI is of limited value in selecting mRCC patients for sequential TKI therapy. There is a strong correlation between the types of tumour response on the first- versus the second TKI.

Keywords

Sunitinib Sorafenib Renal cell carcinoma Response 

Notes

Acknowledgments

The RENIS database is maintained with partial support by Pfizer and Bayer Schering Pharma, the manufacturers of sunitinib and sorafenib, respectively.

Conflict of interest

TB and BM have received honoraria for lectures from Pfizer and Bayer Schering Pharma.

References

  1. 1.
    Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, Grünwald V, Thompson JA, Figlin RA, Hollaender N, Urbanowitz G, Berg WJ, Kay A, Lebwohl D, Ravaud A. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet. 2008;372:449–56.PubMedCrossRefGoogle Scholar
  2. 2.
    Rini BI, Escudier B, Tomczak P, Kaprin A, Szczylik C, Hutson TE, Michaelson MD, Gorbunova VA, Gore ME, Rusakov IG, Negrier S, Ou YC, Castellano D, Lim HY, Uemura H, Tarazi J, Cella D, Chen C, Rosbrook B, Kim S, Motzer RJ. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet. 2011;378:1931–9.PubMedCrossRefGoogle Scholar
  3. 3.
    Buchler T, Klapka R, Melichar B, Brabec P, Dusek L, Vyzula R, Abrahamova J. Sunitinib followed by sorafenib or vice versa for metastatic renal cell carcinoma—data from the Czech registry. Ann Oncol. 2012;23:395–401.PubMedCrossRefGoogle Scholar
  4. 4.
    Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356:115–24.PubMedCrossRefGoogle Scholar
  5. 5.
    Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007;356:125–34.PubMedCrossRefGoogle Scholar
  6. 6.
    Al-Marrawi MY, Rini BI, Harshman LC, Bjarnason GA, Wood L, Vaishampayan UN, MacKenzie MJ, Knox JJ, Agarwal N, Kollmannsberger CK, Tan M, Rha SY, Donskov F, North SA, Choueiri TK, Heng DYC. The association of clinical outcome to front-line VEGF-targeted therapy with clinical outcome to second-line VEGF-targeted therapy in metastatic renal cell carcinoma (mRCC) patients (Pts). J Clin Oncol. 2011; 29 (suppl; abstr 4555).Google Scholar
  7. 7.
    Escudier B, Loomis AK, Kaprin A, Motzer R, Tomczak P, Tarazi J, Kim S, Gao F, Williams JA, Rini B. Association of single nucleotide polymorphisms (SNPs) in VEGF pathway genes with progression-free survival (PFS) and blood pressure (BP) in metastatic renal cell carcinoma (mRCC) in the phase 3 trial of axitinib versus sorafenib (AXIS trial). Eur J Cancer. 2011;47(Suppl 1):S505.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  • Tomas Buchler
    • 1
  • Tomas Pavlik
    • 2
  • Zbynek Bortlicek
    • 2
  • Alexandr Poprach
    • 3
  • Rostislav Vyzula
    • 3
  • Jitka Abrahamova
    • 1
  • Bohuslav Melichar
    • 4
  1. 1.Department of Oncology, First Faculty of MedicineThomayer Hospital and Charles UniversityPragueCzech Republic
  2. 2.Institute of Biostatistics and AnalysesMasaryk UniversityBrnoCzech Republic
  3. 3.Department of Complex Oncology CareMasaryk Memorial Cancer InstituteBrnoCzech Republic
  4. 4.Department of OncologyPalacky University Medical School and Teaching HospitalOlomoucCzech Republic

Personalised recommendations